I am a healthcare professional

Notice


Welcome to MEDICALLY. This website is a non-promotional international resource intended to facilitate transparent scientific exchange regarding developments in medical research and disease management. It is intended for healthcare professionals outside the United Kingdom (UK) and Australia. The content on this website may include scientific information about experimental or investigational compounds, indications and services that are not approved or valid in your jurisdiction. Registration status and prescribing information of medicinal products may differ between countries. Roche and Genentech do not support, endorse or recommend the unapproved use of any compound or service in your jurisdiction, including those discussed on this website.


Please refer to local product information for any medicinal products mentioned. Information available on this website does not constitute professional medical advice, and Roche and Genentech accept no responsibility for access to or use of the same. Healthcare professionals outside the US are required to register and log-in to access the full range of content available on this website.


By clicking on one of the healthcare professional buttons below, you acknowledge you have read and understood this message and that you are requesting access to MEDICALLY. If you are not a healthcare professional, please use the other links below to access information relevant to you.


Cookies


We use cookies on this site to enable the site to function properly and to enhance your user experience. Cookies are files stored in your browser, which most websites use to personalize your web experience. Your information will only be used to provide information that is relevant to you. It will not be used for any other purpose. If you wish to restrict or block cookies, which are set on your device, then you can do this through your browser settings.


You can find out more about cookies by browsing our Privacy Policy.

 

I am a healthcare professional in Canada

Required field.

For healthcare professionals in Another Country browse medically.roche.com.

Not a healthcare professional? For individuals outside the US, browse Roche's patient website or roche.com. For individuals in the US, browse gene.com.

External site

By following this link, you are leaving Medically and entering a website that is not owned or controlled by Roche. Roche does not take any responsibility for access to or use of this website, nor for any content therein.

Leave site
Home Oncology Urinary Bladder Cancer

Urinary Bladder Cancer

What's new

Sign up or login to unlock the full suite of MEDICALLY features
Feb 14 / Roche and Genentech
Effectiveness and Safety of First-Line Atezolizumab in Locally Advanced or Metastatic Urothelial Cancer: The IMFLAME Study
The purpose of this analysis is to evaluate the real-word effectiveness and safety of atezolizumab monotherapy as first line treatment in locally advanced or mUC ineligible for platinum-based chemotherapies.
Oncology Urinary Bladder Cancer ASCO-GU-2025

Sign up or login to unlock the full suite of MEDICALLY features
Sep 15 / Roche and Genentech
Post hoc analysis of outcomes according to prior chemotherapy (CT) response and platinum agent in the international SAUL study of atezolizumab (atezo) for urinary tract carcinoma (UTC)
This poster reports a post hoc analysis of clinical outcomes with atezolizumab in previously treated patients with metastatic urinary tract carcinoma based on response to prior chemotherapy and type of platinum agent, using data from the single-arm prospective SAUL study. Outcomes reported in this subgroup analysis include assesses efficacy, overall survival, overall response rate, and duration of response.
Oncology Urinary Bladder Cancer ESMO-2024

Sign up or login to unlock the full suite of MEDICALLY features
Sep 12 / Roche and Genentech
Bladder preservation therapy in combination with atezolizumab and radiation therapy for invasive bladder cancer (BPT RT): An open label, single arm, multicenter, phase II
This poster presents an open-label, single-arm multicenter Phase II trial evaluating atezolizumab combined with radiation therapy as bladder preservation therapy in patients with invasive bladder cancer. The poster presents data from an interim analysis on efficacy and safety.
Oncology Urinary Bladder Cancer ESMO-2022

Sign up or login to unlock the full suite of MEDICALLY features
Independent content
Sep 18 / Springer Healthcare
ESMO 2021 Genitourinary tumour highlights
Delegates seeking the latest in genitourinary cancer research have been treated to a range of key trial findings in the first days of the ESMO Congress 2021.
Oncology Prostate Cancer Urinary Bladder Cancer
Bookmark this
Share page

Sign up or login to unlock the full suite of MEDICALLY features
Independent content
Sep 18 / Roche and Genentech
What is the optimal perioperative chemotherapy regimen for muscle-invasive bladder cancer?
Srikala Sridhar gives her thoughts on the VESPER V05 trial comparing dose-dense methotrexate, vinblastine, doxorubicin and cisplatin with gemcitabine plus cisplatin as perioperative treatment in people with muscle-invasive bladder cancer.
Oncology Urinary Bladder Cancer ESMO-2021
Bookmark this
Share page

Sign up or login to unlock the full suite of MEDICALLY features
Independent content
Sep 18 / Springer Healthcare
Cetrelimab boosts erdafitinib response in advanced urothelial carcinoma
Srikala Sridhar comments on the interim analysis of the NORSE study of first-line erdafitinib plus cetrelimab in cisplatin-ineligible patients with advanced urothelial carcinoma and fibroblast growth factor receptor alterations.
Oncology Urinary Bladder Cancer ESMO-2021
Bookmark this
Share page

Ask a question or share feedback

Get in touch

This website is intended for healthcare professionals outside the United Kingdom (UK) and Australia. Registration status and prescribing information of medicinal products may differ between countries. Please refer to local product information for any medicinal products mentioned on this website.